ABPI response to consultation on NICE's methods

06 November 2020 Posted in News by Press Office

The ABPI welcomes the publication of today's consultation on NICE's Methods and the launched of a public consultation on proposals for changes to the methods it uses to develop its guidance on medicines, medical devices and diagnostics.

The changes outlined can also act as a catalyst for global investment, with the UK demonstrating its commitment to researching, developing and using new medicines and technologies. Richard Torbett

Chief Executive of the ABPI Richard Torbett said:

“The proposals set out in the consultation are a positive first step towards more NHS patients benefitting from the very latest medicines.

"The changes outlined can also act as a catalyst for global investment, with the UK demonstrating its commitment to researching, developing and using new medicines and technologies.

"Implementation is also fully affordable due to voluntary scheme, which pharmaceutical companies are signed up to, and means that NHS spend on medicines is kept to an agreed and affordable level. We will work our membership on the next stage of the consultation.”

TAGS
  • NICE

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​